

MI3 Market Alert: Next generation pharmaceutical products for unmet medical needs

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Technologies Corp.

- IntelGenx's superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.
- IntelGenx is currently conducting scale-up activities for cannabis-infused oral film product for an anticipated commercial launch. With the recent Cannabis Act amendments authorizing the sale of new classes of cannabis products, including oral films, we are well-positioned participate in the expanded cannabis market just as new product formats come online.
- Rebounding since 70 cents ... next target \$0.93 ...Echelon Wealth Partners rate IGX at \$1.60
- Support: S2; \$0.70 S1; \$0.78 Resistance: R1; \$0.89 R2; \$0.93



About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.